Zobrazeno 1 - 10
of 18
pro vyhledávání: '"A. YAKABOW"'
Autor:
Presant, Cary A., Soloway, Mark S., Klioze, Sol S., Yakabow, Alun, Presant, Seth N., Mendez, Rafael G., Kennedy, Peter S., Wyres, Melody R., Naessig, Virginia L., Todd, Barbara, Wiseman, Charles L., Bouzaglou, Armand, Tanenbaum, Barton, Eventov, Daniel, Presant, C A, Soloway, M S, Klioze, S S, Yakabow, A, Presant, S N, Mendez, R G
Publikováno v:
Cancer (0008543X); May1987, Vol. 59 Issue 10, p1713-1716, 4p
Autor:
Presant, Cary A., Soloway, Mark S., Klioze, Sol S., Kosola, John W., Yakabow, Alun L., Mendez, Rafael G., Kennedy, Peter S., Wyres, Melody R., Naessig, Virginia L., Ford, Kimball S., Wiseman, Charles L., Bouzaglou, Armand, Tanenbaum, Barton, Eventov, Daniel, Presant, C A, Soloway, M S, Klioze, S S, Kosola, J W, Yakabow, A L, Mendez, R G
Publikováno v:
Cancer (0008543X); Nov1985, Vol. 56 Issue 10, p2416-2419, 4p
Autor:
N. Faure, Michael Koutsilieris, S. Klioze, André Lemay, A. Yakabow, A. T. A. Fazekas, George Tolis
Publikováno v:
Journal of Steroid Biochemistry. 19:995-998
Forty-six patients with prostatic carcinoma received the gonadotropin releasing hormone agonistic analogue (GnRH-A) Buserelin at doses ranging from 0.05 to 1.5 mg subcutaneously and/or 0.4 to 1.2 mg intranasally (i.n.) daily for 12-120 weeks. An incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecee9488c7e5758fff9ec3106e8c87f0
https://doi.org/10.1016/0022-4731(83)90045-6
https://doi.org/10.1016/0022-4731(83)90045-6
Autor:
Mark S. Soloway, Armand Bouzaglou, Virginia L. Naessig, Alun L. Yakabow, Daniel Eventov, Melody R. Wyres, Barton Tanenbaum, Sol S. Klioze, Rafael G. Mendez, Seth N. Presant, Barbara Todd, Cary A. Presant, Charles L. Wiseman, Peter S. Kennedy
Publikováno v:
Cancer. 59:1713-1716
The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stages C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one comple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce9ebbf79d077ae7f15061e81f95cee2
https://doi.org/10.1002/1097-0142(19870515)59:10<1713::aid-cncr2820591006>3.0.co
https://doi.org/10.1002/1097-0142(19870515)59:10<1713::aid-cncr2820591006>3.0.co
Autor:
Armand Bouzaglou, Peter S. Kennedy, Virginia L. Naessig, Melody R. Wyres, Daniel Eventov, Mark S. Soloway, Kimball S. Ford, John W. Kosola, Charles L. Wiseman, Sol S. Klioze, Alun L. Yakabow, Rafael G. Mendez, Barton Tanenbaum, Cary A. Presant
Publikováno v:
Cancer. 56:2416-2419
The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1f1b867dc8ce31571c2aee13786a1bc
https://doi.org/10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co
https://doi.org/10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co
Autor:
C A, Presant, M S, Soloway, S S, Klioze, A, Yakabow, S N, Presant, R G, Mendez, P S, Kennedy, M R, Wyres, V L, Naessig, B, Todd
Publikováno v:
Cancer. 59(10)
The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stages C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one comple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::47ea6b611ea826211acae682df37a75a
https://pubmed.ncbi.nlm.nih.gov/3103904
https://pubmed.ncbi.nlm.nih.gov/3103904
Autor:
C A, Presant, M S, Soloway, S S, Klioze, J W, Kosola, A L, Yakabow, R G, Mendez, P S, Kennedy, M R, Wyres, V L, Naessig, K S, Ford
Publikováno v:
Cancer. 56(10)
The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::07c5eac30d5fa03ab672dacbd707cdbd
https://pubmed.ncbi.nlm.nih.gov/3930064
https://pubmed.ncbi.nlm.nih.gov/3930064
Publikováno v:
The Journal of clinical psychiatry. 45(4 Pt 2)
During the clinical development of nomifensine maleate (Merital), 1319 depressed patients received nomifensine (average doses of 150 mg/day) in 4-6 week trials; treatment was continued for at least 2 months in 170 patients and at least 6 months in 53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::944572658085a91ed410d254b0507873
https://pubmed.ncbi.nlm.nih.gov/6370985
https://pubmed.ncbi.nlm.nih.gov/6370985
Autor:
A. Yakabow, S. Klioze, A. Stellos, George Tolis, H. Adenauer, A. T. A. Fazekas, Michael Koutsilieris
Publikováno v:
Acta Endocrinologica. 104:S22-S23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464d03cd17e2bb633ad6be06d93247ea
https://doi.org/10.1530/acta.0.107s0022
https://doi.org/10.1530/acta.0.107s0022